Novel Therapeutics in Acute Myeloid Leukemia

Am Soc Clin Oncol Educ Book. 2017:37:495-503. doi: 10.1200/EDBK_175401.

Abstract

In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.

Publication types

  • Review

MeSH terms

  • Aminopyridines / therapeutic use
  • Humans
  • Isocitrate Dehydrogenase / antagonists & inhibitors*
  • Isocitrate Dehydrogenase / genetics
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / pathology
  • Molecular Targeted Therapy*
  • Mutation
  • Triazines / therapeutic use
  • fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Aminopyridines
  • Triazines
  • enasidenib
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3